NEWS HIGHLIGHTSMedia Articles Related to Keppra XR (Levetiracetam)
NeuroTherapeutics Pharma Receives Investment From The Epilepsy Therapy Project
Source: Epilepsy News From Medical News Today [2009.11.11]
NeuroTherapeutics Pharma, Inc., or NTP, a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, today announced that it received a $100,000 investment from the Epilepsy Therapy Project. The Epilepsy Therapy Project invests in promising research efforts in order to help make new therapies a reality for patients, and the investment in NTP is one of the largest made in its history.
Ikano Therapeutics Receives Orphan Drug Designation For Epilepsy Drug
Source: Epilepsy News From Medical News Today [2009.11.11]
Ikano Therapeutics, Inc. (ITI) announced that it has received Orphan Drug designation for midazolam in the acute treatment of certain forms of epileptic seizure known as cluster seizures or alternatively, as acute repetitive seizures. ITI has a nasally administered form of midazolam called ITI-111 in late stage clinical development that is aimed at the treatment of these specific seizure types in an outpatient setting where other routes of administration can be difficult or inappropriate.
Alzheimer's Society Comment On The Use Of Epilepsy Drugs To Treat Alzheimer's
Source: Epilepsy News From Medical News Today [2009.10.29]
Epilepsy drugs could be developed as a treatment for neurodegenerative diseases according to research published in the journal Molecular Neurodegeneration. The study found that nerve cells lived longer when treated with T-type calcium-channel blockers, which are commonly used to treat epilepsy. 'This study is interesting since other research has shown that anti-convulsant drugs reduce the tangles of proteins linked to Alzheimer's disease.
Alzheimer's And Parkinson's Could Be Treated By Epilepsy Drugs
Source: Epilepsy News From Medical News Today [2009.10.29]
Researchers in the USA have discovered a potential new function for anti-epileptic drugs in treating neurodegenerative disorders such as Alzheimer's and Parkinson's disease. The study, published in BioMed Central's open access journal Molecular Neurodegeneration, found that neurons in the brain were protected after treatment with T-type calcium-channel blockers, which are commonly used to treat epilepsy.
Epilepsy Treatment Is A Possible Culprit For Development Of Schizophrenia
Source: Epilepsy News From Medical News Today [2009.10.21]
Researchers say antiepilectic drug treatments administered when the brain is developing appear to trigger schizophrenia-like behavior in animal models. In humans, having a history of seizures in infancy is a significant risk factor for development of schizophrenia later in life, but it is not known whether the elevated risk is due to seizures themselves, or from side effects antiepileptic drug (AED) treatment.
Published Studies Related to Keppra XR (Levetiracetam)
Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: A randomized, double-blind, placebo-controlled, noninferiority trial. [2009.08.21]
Summary Purpose: Evaluate potential neurocognitive effects of adjunctive levetiracetam in children with inadequately controlled partial-onset seizures (POS)... Levetiracetam was effective and well tolerated.
Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. [2009.07]
PURPOSE: To assess the efficacy and tolerability of adjunctive levetiracetam in idiopathic generalized epilepsy (IGE) syndromes with onset during adolescence: juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and generalized tonic-clonic seizures on awakening (GTCSA)... CONCLUSIONS: Adjunctive levetiracetam was well tolerated and provided effective seizure control over 16-24 weeks in patients with insufficiently controlled IGE syndromes with onset during adolescence (JAE, JME, and GTCSA), supporting levetiracetam's broad spectrum of efficacy.
Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. [2009.07]
Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures. PHT, however, has many undesirable side effects (SEs) and drug interactions with glioma chemotherapy...
Levetiracetam in spinal cord injury pain: a randomized controlled trial. [2009.06.09]
Study design:A randomized, double-blind, placebo-controlled, crossover, multicenter trial. A 1-week baseline period was followed by two treatment periods of 5 weeks duration with levetiracetam increased from 500 mg b.i.d... Only two patients continued levetiracetam treatment following the trial, and one patient was still in levetiracetam treatment at the 6-month follow-up.
Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia. [2009.06]
BACKGROUND AND PURPOSE: The objective of this study was to determine whether levetiracetam (LEV) is an effective drug for treatment of trigeminal neuralgia (TN)... CONCLUSION: Given its established safety profile, a randomized, placebo-controlled, double-blind trial of LEV using enhancement enrollment design is needed to confirm these open-labelled findings using a wide variety of outcome measures.
Clinical Trials Related to Keppra XR (Levetiracetam)
Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study) [Recruiting]
Assess the Safety and Efficacy of a Seizure Medication,Levetiracetam(LEV;Keppra),in Neuroscience Intensive Care Unit Patients [Recruiting]
To show that the use of intravenous levitiracetam(LEV;Keppra)for seizure prevention in
patients in the Neuroscience Intensive Care Unit will result in fewer side effects compared
to the current standard of care anticonvulsant and will be at least as effective as the
current standard of care in preventing clinical and sub-clinical seizure activity.
Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy [Recruiting]
Keppra injection is approved in the US as adjunctive therapy in the treatment of partial
onset seizures in adults with epilepsy. The objective of the current study is to assess the
pharmacokinetics, safety and tolerability of this formulation in children aged 4 to 16
years.
Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy [Recruiting]
Keppra injection is approved in the US as adjunctive therapy in the treatment of partial
onset seizures in adults with epilepsy. The objective of the current study is to assess the
pharmacokinetics, safety and tolerability of this formulation in children aged 1 month to 4
years.
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy [Recruiting]
The purpose of this trial is to study how the body absorbs, distributes, metabolizes and
eliminates Keppra XR in both teenagers (12 to 16 years old) and adults (18 and 55 years old)
with epilepsy.
|
